Table I. Characteristics of early-stage COVID-19 patients.
| Influenza Patients (n = 13) | COVID-19 Patients (n = 15) | |
|---|---|---|
| Male | 8 (61.5%) | 7 (46.7%) |
| Female | 5 (38.5%) | 8 (53.3%) |
| Age, year | 57.0 (20.0-90.0) | 41.0 (6.0-68.0) |
| SARS-CoV-2 (+) | 0 | 15 (100%) |
| FluA-RNA (+) | 6 (46.2%) | 0 |
| FluB RNA (+) | 3 (23%) | 0 |
| RSV RNA (+) | 4 (30.8%) | 0 |
| Disease stage | ||
| Mild | 5 (38.5%) | 4 (26.7%) |
| Moderate | / | 11 (73.3%) |
| Severe | 7 (53.8%) | 0 |
| Critical | 1 (7.7%) | 0 |
| Exposure history | 4 (30.8%) | 14 (93.3%) |
| Symptoms | ||
| Fever | 13 (100%) | 11 (73.3%) |
| Headache | 4 (30.8%) | 1 (6.7%) |
| Cough | 6 (46.2%) | 7 (46.7%) |
| Sputum | 3 (23.1%) | 2 (13.3%) |
| Myalgia | 7 (53.8%) | 2 (13.3%) |
| Fatigue | 6 (46.2%) | 0 |
| Dyspnea | 1 (7.7%) | 2 (13.3%) |
| Nasal congestion/Rhinorrhoea | 4 (30.8%) | 4 (26.7%) |
| Sore throat | 4 (30.8%) | 5 (33.3%) |
| Pleuritic chest pain | 1 (7.7%) | 2 (13.3%) |
| Abdominal pain | 1 (7.7%) | 1 (6.7%) |
| Diarrhea | 1 (7.7%) | 0 |
| Nausea or vomiting | 0 | 0 |
| Asymptom | 0 | 2 (13.3%) |
| Onset of symptom, Median ± S.D., days | 5.5 ± 6.3 | 4.2 ± 4.6 |
| Pneumonia | 8 (61.5%) | 11 (73.3%) |
| Chest CT | ||
| Pulmonary ground-glass opacity | 7 (53.8%) | 11 (73.3%) |
| Bilateral pulmonary infiltration | 6 (46.2%) | 10 (66.7%) |
| Administrated drugs | 0 | 0 |
| Comorbidities | ||
| Pulmonary diseases | 0 | 1 (6.7%) |
| Cardiovascular diseases | 2 (15.4%) | 0 |
| Tumor | 1 (7.7%) | 0 |
| Endocrine diseases | 2 (15.4%) | 0 |
| None | 8 (61.5%) | 14 (93.3%) |
Data are median (IQR) or n (%).